Rodríguez Garzotto, Analía Díaz García, C. Vanesa Agudo López, Alba Prieto García, Elena Ponce Aix, Santiago López Martín, José Antonio Paz-Ares Rodríguez, Luis Iglesias Docampo, Lara Agulló Ortuño, María Teresa
Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. [artículo] - Medical oncology (Northwood, London, England), 2016 - 33(10):105.
Formato Vancouver:
Rodríguez Garzotto A, Díaz García CV, Agudo López A, Prieto García E, Ponce S, López Martín JA et al. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. Med Oncol. 2016 Oct;33(10):105.
PMID: 27568331
Contiene 40 referencias
Tumor angiogenesis pathways have been identified as important therapeutic targets in non-small cell lung cancer. However, no biomarkers have been described as predictors of response to antiangiogenic therapy in these patients. In this study, plasma levels of VEGF, bFGF, E-selectin, and S-ICAM and gene expression profiles of peripheral blood mononuclear cells from non-small cell lung cancer patients treated with chemotherapy plus bevacizumab were analyzed before and after treatment. Values were correlated with clinicopathological characteristics and treatment response. Plasma factor levels were measured using commercially available ELISA kits. The TaqMan(®) human angiogenesis array was used to investigate the effect of treatment on gene expression profiles. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology enrichment analysis was performed for differentially expressed genes using WEB-based GEne SeT AnaLysis Toolkit. Our results suggest a benefit for patients with increased plasma levels of VEGF, E-selectin, and S-ICAM in the course of bevacizumab treatment. Also, we identified differentially expressed genes between paired blood samples from patients before and after treatment, and significantly perturbed pathways were predicted. These changes in gene expression and levels of plasma factors could be used to assess the effectiveness of antiangiogenic therapy, in addition to standard clinical and radiological evaluations.
Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. [artículo] - Medical oncology (Northwood, London, England), 2016 - 33(10):105.
Formato Vancouver:
Rodríguez Garzotto A, Díaz García CV, Agudo López A, Prieto García E, Ponce S, López Martín JA et al. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. Med Oncol. 2016 Oct;33(10):105.
PMID: 27568331
Contiene 40 referencias
Tumor angiogenesis pathways have been identified as important therapeutic targets in non-small cell lung cancer. However, no biomarkers have been described as predictors of response to antiangiogenic therapy in these patients. In this study, plasma levels of VEGF, bFGF, E-selectin, and S-ICAM and gene expression profiles of peripheral blood mononuclear cells from non-small cell lung cancer patients treated with chemotherapy plus bevacizumab were analyzed before and after treatment. Values were correlated with clinicopathological characteristics and treatment response. Plasma factor levels were measured using commercially available ELISA kits. The TaqMan(®) human angiogenesis array was used to investigate the effect of treatment on gene expression profiles. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology enrichment analysis was performed for differentially expressed genes using WEB-based GEne SeT AnaLysis Toolkit. Our results suggest a benefit for patients with increased plasma levels of VEGF, E-selectin, and S-ICAM in the course of bevacizumab treatment. Also, we identified differentially expressed genes between paired blood samples from patients before and after treatment, and significantly perturbed pathways were predicted. These changes in gene expression and levels of plasma factors could be used to assess the effectiveness of antiangiogenic therapy, in addition to standard clinical and radiological evaluations.
